| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 87346 |
DOTA-NOC ；619300-53-7 |
110 |
wyh |
2024-11-21 |
| 87347 |
DOTA-奥曲肽,DOTA-Octreotide |
161 |
zyl |
2024-11-21 |
| 87348 |
DOTA-PEG5-amine ；DOTA-PEG5-NH2 |
98 |
wyh |
2024-11-21 |
| 87349 |
DOTA修饰肽,1180007-00-4,二肽Z-GGRDOTA |
99 |
zyl |
2024-11-21 |
| 87350 |
DOTA-PEG5-amine ；DOTA-PEG5-NH2 |
98 |
wyh |
2024-11-21 |
| 87351 |
DOTA-RGD,DOTA-cRGDfK |
157 |
zyl |
2024-11-21 |
| 87352 |
DOTA-Lys-Cys-Acid 二肽DOTA-Lys-Cys |
123 |
wyh |
2024-11-21 |
| 87353 |
DOTA-Ala-Ala-COOH ；DOTA-丙氨酸-丙氨酸-羧酸 |
136 |
wyh |
2024-11-21 |
| 87354 |
cas:1293368-74-7,DOTA标记的多肽 |
147 |
zyl |
2024-11-21 |
| 87355 |
Azido-mono-amide-DOTA ；1227407-76-2 |
86 |
wyh |
2024-11-21 |
| 87356 |
Gd-DOTA-HCBP-1(多肽核磁共振成像(MRI)探针) |
123 |
zyl |
2024-11-21 |
| 87357 |
DOTA octreotide,大环配体奥曲肽 |
157 |
zyl |
2024-11-21 |
| 87358 |
DOTA-(D-Gln)3-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2，DOTA修饰多肽 |
91 |
zyl |
2024-11-21 |
| 87359 |
二聚体多肽 cas:250612-06-7 dota-glu[cyclo(arg-gly-asp-d-phe-lys)]2 |
137 |
zyl |
2024-11-21 |
| 87360 |
DBCO-SS-PEG-DOTA 二苯并环辛炔-聚乙二醇之四氮杂环十二烷 |
115 |
zyl |
2024-11-21 |
| 87361 |
(R)-C3-TUNAPHOS，cas:301847-89-2， R -( - )-1,13 -双(二苯基膦)-7,8 -二氢的6H -二苯H |
147 |
zcy |
2024-11-21 |
| 87362 |
Br-C3-methyl ester，cas:4897-84-1，4-溴丁酸甲酯 |
134 |
zcy |
2024-11-21 |
| 87363 |
DOTA-(COOt-Bu)3-C4-NH2，1402393-59-2，烷基链化合物或碳链化合物 |
134 |
zcy |
2024-11-21 |
| 87364 |
Gal-C4-Chol，cas:219850-70-1，糖基化胆固醇衍生物 |
163 |
zcy |
2024-11-21 |
| 87365 |
DOTAGA-DTyr(3I)-DPhe-DLys(Sub-Lys-urea-Glu) |
103 |
zyl |
2024-11-21 |
| 87366 |
Boc-C1-PEG2-C4-Cl，cas:1835705-53-7，烷基链化合物或碳链化合物 |
98 |
zcy |
2024-11-21 |
| 87367 |
AP-C6，cas:2234276-60-7， 烷基链化合物或碳链化合物 |
150 |
zcy |
2024-11-21 |
| 87368 |
cas:467456-19-5，6-(N-6-羟基己基)酰胺荧光素， 6-FAM-C6-OH |
235 |
zcy |
2024-11-21 |
| 87369 |
1262403-91-7 ；七肽DOTA-YLYEIAR |
142 |
wyh |
2024-11-21 |
| 87370 |
cas:1261350-60-0，NH2-PEG3-C6-Cl，烷基链化合物或碳链化合物 |
137 |
zcy |
2024-11-21 |
| 87371 |
...RGD,[18F]FB-c(RGDyK),N-4-[18F]Fluorobenzoyl-c(RGDyK... |
129 |
wyh |
2024-11-21 |
| 87372 |
C6 Urea Ceramide，cas:486991-52-0，D-赤型-N-[2-(1,3-二羟基-4E-十八碳烯)]-N'-己烷-脲-鞘氨醇 |
96 |
zcy |
2024-11-21 |
| 87373 |
1262403-90-6 ；七肽DOTA-VLASSAR |
134 |
wyh |
2024-11-21 |
| 87374 |
SPDP-C6-NHS ester，cas:158913-22-5，琥珀酰亚胺基-6-[3-(2-吡啶基二硫基)丙酰胺基]己酸 |
190 |
zcy |
2024-11-21 |
| 87375 |
海藻酸钠-聚乙二醇-大环配体 ；alginate-PEG-DOTAM |
126 |
wyh |
2024-11-21 |
| 87376 |
C6 D-threo Ceramide (d18:1/6:0)，cas:189894-79-9，鞘氨醇衍生物 |
189 |
zcy |
2024-11-21 |
| 87377 |
DOTA-(COOt-Bu)3-azide，1402795-92-9 |
101 |
wyh |
2024-11-21 |
| 87378 |
cas:1957235-98-1；Thalidomide-NH-C6-NH2 hydrochloride；沙利度胺衍生物 |
110 |
zcy |
2024-11-21 |
| 87379 |
DOTA-cyclo(Arg-Gly-Asp-DPhe-Lys) |
125 |
wyh |
2024-11-21 |
| 87380 |
DOTA-TMTP1的结构与组成 |
151 |
wyh |
2024-11-21 |
| 87381 |
DOTA-MeTz，1610950-41-8，DOTA-甲基四嗪 |
104 |
zyl |
2024-11-21 |
| 87382 |
DOTA-c(RGDfK)的结构特点 |
117 |
wyh |
2024-11-21 |
| 87383 |
C6 NBD Ceramide，N-[6-[(7-硝基-2-1,3-苯并恶二唑-4-基)氨基]己酰基] -D-赤型-鞘氨醇 |
268 |
zcy |
2024-11-21 |
| 87384 |
DOTA-「Tyr3」-Octreotide ；204318-14-9 |
112 |
wyh |
2024-11-21 |
| 87385 |
cas:619300-53-7 DOTA NOC acetate |
111 |
zyl |
2024-11-21 |
| 87386 |
p-SCN-Bn-DOTA ；127985-74-4 |
106 |
wyh |
2024-11-21 |
| 87387 |
cas:2093386-51-5，Thalidomide-NH-C6-NH2 TFA，烷基链化合物或碳链化合物 |
201 |
zcy |
2024-11-21 |
| 87388 |
913528-04-8 ；DOTAM-mono-acid-CSDN |
117 |
wyh |
2024-11-21 |
| 87389 |
1039726-31-2 ；DOTA-JR-11 |
109 |
wyh |
2024-11-21 |
| 87390 |
Thalidomide-O-C6-NH2，cas:1957235-98-1，烷基链化合物或碳链化合物 |
151 |
zcy |
2024-11-21 |
齐岳微信公众号
官方微信
库存查询